We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Regulatory T Cells Hamper Fight Against Cancer

By Biotechdaily staff writers
Posted on 23 Sep 2002
Researchers have found that while some cancer patients develop specific cytolytic lymphocytes that should destroy their tumors, these cells are prevented from acting due to a chemical signal transmitted by another set of immune cells called regulatory T cells. More...
The finding was published in the September 15, 2002, issue of Cancer Research.

Studies of the interaction between human colorectal cancer cells and immune cells revealed that transforming growth factor (TGF-beta) was the chemical messenger that prevented cytolytic T cells from acting. The researchers say a drug that inactivates the regulatory T cells or that blocks the TGF-beta chemical message they send might free the cytolytic T cells to attack a patient's tumor.

"We have known for some time that cancer patients can generate T cells able to attack their tumors,” explained senior author Dr. Dorothee Herlyn, a professor at The Wistar Institute (Philadelphia, PA, USA; www.wistar.edu). "What we discovered in this study is that those patients also produce negatively regulating cells at the same time that keep the attacking T cells in check. The existence of these regulatory cells may help explain how tumors are able to evade the immune system. They also represent a new starting point for thinking about novel anticancer treatments.”




Related Links:
The Wistar Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gold Member
Platelet Function Analyzer
PL-12
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.